Ventyx Biosciences, Inc. (VTYX)

NASDAQ: VTYX · IEX Real-Time Price · USD
6.05
+0.19 (3.24%)
At close: Feb 27, 2024, 4:00 PM
6.41
+0.36 (5.95%)
Pre-market: Feb 28, 2024, 4:00 AM EST
3.24%
Market Cap 346.02M
Revenue (ttm) n/a
Net Income (ttm) -192.96M
Shares Out 59.05M
EPS (ttm) -3.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,574,672
Open 6.01
Previous Close 5.86
Day's Range 5.54 - 6.18
52-Week Range 1.87 - 47.25
Beta -1.05
Analysts Hold
Price Target 20.67 (+241.65%)
Earnings Date Feb 27, 2024

About VTYX

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. Its lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhi... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 21, 2021
Employees 99
Stock Exchange NASDAQ
Ticker Symbol VTYX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for VTYX stock is "Hold." The 12-month stock price forecast is $20.67, which is an increase of 241.65% from the latest price.

Price Target
$20.67
(241.65% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Ventyx Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Corporate Progress

Ventyx to host virtual investor event on March 11 th to provide clinical updates on our NLRP3 portfolio and from the open-label extension of the VTX002 Phase 2 trial in ulcerative colitis

12 hours ago - GlobeNewsWire

Ventyx Biosciences to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a bro...

21 days ago - GlobeNewsWire

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / January 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ventyx Bioscie...

6 weeks ago - Accesswire

IMPORTANT INVESTOR ALERT: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / January 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ventyx Bioscien...

7 weeks ago - Accesswire

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / December 28, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ventyx Biosci...

2 months ago - Accesswire

Ventyx Biosciences to Participate in the 35th Annual Piper Sandler Healthcare Conference

SAN DIEGO, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a bro...

3 months ago - GlobeNewsWire

VENTYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Ventyx Biosciences, Inc. on Behalf of Ventyx Stockholders and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Ventyx Biosciences, Inc. (“Ventyx” or the “C...

3 months ago - Business Wire

Ventyx Biosciences to Participate in the Jefferies London Healthcare Conference

SAN DIEGO, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a bro...

3 months ago - GlobeNewsWire

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / November 9, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ventyx Bioscie...

3 months ago - Accesswire

Ventyx Biosciences Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate Progress

Ventyx to provide updates across clinical-stage portfolio in the first quarter of 2024 Cash, cash equivalents and marketable securities of $300.8 million as of September 30, 2023 SAN DIEGO, Nov. 09, 2...

3 months ago - GlobeNewsWire

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Ventyx Biosciences, Inc. (VTYX)

NEW YORK--(BUSINESS WIRE)---- $VTYX #classactionlawsuit--The law firm of Kirby McInerney LLP is investigating potential claims against Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) (NASDAQ: VTY...

3 months ago - Business Wire

Ventyx Biosciences' stock suffering record plunge after psoriasis treatment trial fails to meet internal efficacy target

Shares of Ventyx Biosciences Inc. VTYX, -9.56% plunged 73.7% in premarket trading Tuesday, after the biopharmaceutical company said it has decided not to support further development of its plaque psor...

4 months ago - Market Watch

Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Patients with Moderate to Severe Plaque Psoriasis and Provides Corporate Update

VTX958 225 mg BID and 300 mg BID doses achieved statistical significance on the primary endpoint (PASI 75) and all key secondary endpoints at Week 16

4 months ago - GlobeNewsWire

Ventyx Biosciences Announces Positive Results from the Phase 2 Trial of VTX002 in Patients with Moderate-to-Severely Active Ulcerative Colitis

VTX002 60 mg achieved the primary endpoint of clinical remission with a high rate of complete endoscopic remission Both 30 mg and 60 mg doses of VTX002 demonstrated an excellent safety and tolerabilit...

5 months ago - GlobeNewsWire

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

SAN DIEGO, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a bro...

6 months ago - GlobeNewsWire

Ventyx Biosciences Reports Second Quarter 2023 Financial Results and Highlights Recent Corporate Progress

Completed enrollment in the Phase 2 trial of VTX002 (S1P1R modulator) in ulcerative colitis and the Phase 2 trial of VTX958 (TYK2 inhibitor) in plaque psoriasis, with topline readouts expected in Q4 2...

7 months ago - GlobeNewsWire

Ventyx Biosciences to Participate in the Canaccord Genuity 43rd Annual Growth Conference

SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a bro...

7 months ago - GlobeNewsWire

Ventyx Biosciences Announces Initiation of Dosing in a Phase 1 Trial of VTX3232, a Novel CNS-Penetrant NLRP3 Inhibitor

Topline data from the Phase 1 SAD/MAD trial of VTX3232 are expected in H1 2024 Topline data from the Phase 1 SAD/MAD trial of VTX3232 are expected in H1 2024

9 months ago - GlobeNewsWire

Ventyx Biosciences Announces Completion of Enrollment of the Phase 2 Trial of VTX002 in Ulcerative Colitis and the Phase 2 Trial of VTX958 in Plaque Psoriasis

Topline results from the Phase 2 trial of VTX002 (S1P1R modulator) in ulcerative colitis and the Phase 2 trial of VTX958 (TYK2 inhibitor) in plaque psoriasis are expected in Q4 2023 Topline results fr...

9 months ago - GlobeNewsWire

Ventyx Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Progress

Phase 2 trials of VTX958 (TYK2 inhibitor) are ongoing in plaque psoriasis, Crohn's disease and psoriatic arthritis, with topline data in plaque psoriasis expected in Q4 2023

10 months ago - GlobeNewsWire

Ventyx Biosciences to Report First Quarter 2023 Financial Results on May 11, 2023

ENCINITAS, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that addre...

10 months ago - GlobeNewsWire

Where Is The Current Bull Market? Scan Of Stocks Gaining Over 20% Over The Past Week Almost Exclusively Yields Biotech Names

Where is the current bull market? All indications would be that it's in biotech!

11 months ago - Benzinga

Ventyx Biosciences to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

ENCINITAS, Calif., March 24, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that addr...

1 year ago - GlobeNewsWire

Ventyx Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Corporate Progress

Phase 2 trials of VTX958 (TYK2 inhibitor) are ongoing in plaque psoriasis, Crohn's disease and psoriatic arthritis, with topline Phase 2 data in plaque psoriasis expected in Q4 2023

1 year ago - GlobeNewsWire

Ventyx Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 23, 2023

ENCINITAS, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that add...

1 year ago - GlobeNewsWire